Literature DB >> 16508725

Early renal cell cancer.

Yoshihiko Tomita1.   

Abstract

Renal cell cancer (RCC) mostly arises from the proximal renal tubules and is classified as an adenocarcinoma. The most reliable treatment for RCC is surgical excision; chemotherapy or radiotherapy does not have a practical effect on RCC. In selected patients, immunotherapy, including cytokine administration, has survival benefits. There is no established definition of early RCC. Surgical removal of organ-confined disease (T1 and T2) is likely to achieve tumor-free status leading to good prognosis. Possible definitions, diagnosis and treatment options for T1 and T2 disease are discussed.

Entities:  

Mesh：

Year:  2006        PMID： 16508725     DOI： 10.1007/s10147-005-0551-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


  55 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

Review 2.  An update of the Bosniak renal cyst classification system.

Authors:  Gary M Israel; Morton A Bosniak
Journal:  Urology       Date:  2005-09       Impact factor: 2.649

3.  A survey on incidental renal cell carcinoma in Japan.

Authors:  Y Aso; Y Homma
Journal:  J Urol       Date:  1992-02       Impact factor: 7.450

4.  Pathological stage does not alter the prognosis for renal lesions determined to be stage T1 by computerized tomography.

Authors:  William W Roberts; Sam B Bhayani; Mohamad E Allaf; Theresa Y Chan; Louis R Kavoussi; Thomas W Jarrett
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

Review 5.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

6.  Defining the complications of cryoablation and radio frequency ablation of small renal tumors: a multi-institutional review.

Authors:  D Brooke Johnson; Stephen B Solomon; Li-Ming Su; Edward D Matsumoto; Louis R Kavoussi; Stephen Y Nakada; Timothy D Moon; W Bruce Shingleton; Jeffrey A Cadeddu
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

7.  A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate?

Authors:  Ricardo F Sánchez-Ortiz; Lydia T Madsen; Carlos E Bermejo; Sijin Wen; Yu Shen; David A Swanson; Christopher G Wood
Journal:  Cancer       Date:  2004-11-15       Impact factor: 6.860

8.  Reassessment of the 1997 TNM classification system for renal cell carcinoma.

Authors:  James M Elmore; Keith T Kadesky; Kenneth S Koeneman; Arthur I Sagalowsky
Journal:  Cancer       Date:  2003-12-01       Impact factor: 6.860

9.  Application of TNM, 2002 version, in localized renal cell carcinoma: is it able to predict different cancer-specific survival probability?

Authors:  Vincenzo Ficarra; Giacomo Novara; Antonio Galfano; Giovanni Novella; Dionisio Schiavone; Walter Artibani
Journal:  Urology       Date:  2004-06       Impact factor: 2.649

10.  Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer.

Authors:  Seiichiro Ozono; Noriomi Miyao; Tatsuo Igarashi; Ken Marumo; Hayakazu Nakazawa; Momokuni Fukuda; Tomoyasu Tsushima; Noriaki Tokuda; Juichi Kawamura; Masaru Murai
Journal:  Jpn J Clin Oncol       Date:  2004-02       Impact factor: 3.019
View more
  2 in total

1.  Nox4 is a Target for Tuberin Deficiency Syndrome.

Authors:  Qian Shi; Suryavathi Viswanadhapalli; William E Friedrichs; Chakradhar Velagapudi; Cédric Szyndralewiez; Shweta Bansal; Manzoor A Bhat; Goutam Ghosh Choudhury; Hanna E Abboud
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

2.  Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.

Authors:  Gorka Larrinaga; Jon Danel Solano-Iturri; Peio Errarte; Miguel Unda; Ana Loizaga-Iriarte; Amparo Pérez-Fernández; Enrique Echevarría; Aintzane Asumendi; Claudia Manini; Javier C Angulo; José I López
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.